Background: Skin rejuvenation has become an increasingly popular noninvasive approach to address age-related changes such as sagging, wrinkles, and skin laxity. Energy-based devices (EBDs) and injectables are widely used, but their application requires careful customization based on individual patient characteristics to optimize outcomes and minimize potential adverse effects. Objective: This study aimed to explore clinical practice patterns among board-certified dermatologists in South Korea, focusing on their strategies for tailoring skin rejuvenation treatments to individual patients, including the integration of EBDs, injectables, and senotherapeutics. Methods: A structured survey comprising 10 questions was administered to 13 experienced dermatologists specializing in skin rejuvenation. The survey covered treatment strategies for patients with varying facial fat volumes, pain management approaches, and the use of EBDs, injectables and senotherapeutics. Results: High-intensity focused ultrasound (HIFU) and radiofrequency (RF) were the most employed EBDs, often combined with injectables for enhanced outcomes. For patients with higher facial fat, HIFU and deoxycholic acid injections were preferred for contouring and tightening. For those with lower facial fat, biostimulatory agents such as poly-D, L-lactic acid and microneedle RF were favored to restore volume and elasticity. Pain management strategies included topical anesthetics and stepwise protocols. Although less commonly used, senotherapeutics were occasionally prescribed for specific conditions, such as melasma and extensive photoaging. Conclusion Dermatologists in South Korea employ a variety of patient-specific strategies for skin rejuvenation, combining various EBDs, injectables, and senotherapeutics. These findings highlight the importance of personalized treatment protocols and the need for further research to optimize treatment efficacy and safety.

Natural killer (NK) cells are pivotal innate immune system components that exhibit spontaneous cytolytic activity against abnormal cells, such as infected and tumor cells. NK cells have shown significant promise in adoptive cell therapy because of their favorable safety profiles and minimal toxicity in clinical settings. Despite their advantages, the therapeutic application of unmodified NK cells faces challenges, including limited in vivo persistence, particularly in the immunosuppressive tumor microenvironment. Recent advances in genetic engineering have enhanced the therapeutic potential of NK cells by addressing these limitations and improving their therapeutic efficacy. In this review, we have described various methodologies for the genetic modification of NK cells, including viral vectors, electroporation, and nanoparticle-based approaches. The ongoing research on nanomaterialbased approaches highlights their potential to overcome current limitations in NK cell therapy, paving the way for advanced cancer therapy and improved clinical outcomes. In this review, we also emphasize the potential of engineered NK cells in cancer immunotherapy and other clinical applications, highlighting the expanding scope of NK cell-based treatments and the critical role of innovative genetic engineering techniques.

Purpose: To report an iris metastasis of non-small-cell lung cancer inducing anterior uveitis and secondary glaucoma.Case summary: A 63-year-old woman presented to our hospital with vision impairment and pain in her right eye. She had been receiving systemic chemotherapy and radiation therapy to manage non-small-cell lung cancer for 2 years. Her best-corrected visual acuities were 25/40 oculus dexter (OD) and 20/25 oculus sinister; intraocular pressure was 52 mmHg OD. Slit-lamp examination revealed multiple round iris nodules and a 1+ inflammatory response in the anterior chamber of the right eye. Despite the maximimal tolerated medical therapy and laser trabeculotomy, the intraocular pressure was not controlled. Because iris metastasis of non-small-cell lung cancer was suspected, aqueous humor cytology and iris tissue biopsy were performed. Cytological analysis did not reveal malignant cells, but histopathological examination confirmed iris metastasis of non-small-cell lung cancer. A restaging procedure for lung cancer was performed, revealing new findings of lung and pelvic bone metastasis. Conclusions Through histopathological examination, it is possible to confirm iris metastasis of malignant tumors. Op

Purpose: To report an iris metastasis of non-small-cell lung cancer inducing anterior uveitis and secondary glaucoma.Case summary: A 63-year-old woman presented to our hospital with vision impairment and pain in her right eye. She had been receiving systemic chemotherapy and radiation therapy to manage non-small-cell lung cancer for 2 years. Her best-corrected visual acuities were 25/40 oculus dexter (OD) and 20/25 oculus sinister; intraocular pressure was 52 mmHg OD. Slit-lamp examination revealed multiple round iris nodules and a 1+ inflammatory response in the anterior chamber of the right eye. Despite the maximimal tolerated medical therapy and laser trabeculotomy, the intraocular pressure was not controlled. Because iris metastasis of non-small-cell lung cancer was suspected, aqueous humor cytology and iris tissue biopsy were performed. Cytological analysis did not reveal malignant cells, but histopathological examination confirmed iris metastasis of non-small-cell lung cancer. A restaging procedure for lung cancer was performed, revealing new findings of lung and pelvic bone metastasis. Conclusions Through histopathological examination, it is possible to confirm iris metastasis of malignant tumors. Op

Purpose: To report an iris metastasis of non-small-cell lung cancer inducing anterior uveitis and secondary glaucoma.Case summary: A 63-year-old woman presented to our hospital with vision impairment and pain in her right eye. She had been receiving systemic chemotherapy and radiation therapy to manage non-small-cell lung cancer for 2 years. Her best-corrected visual acuities were 25/40 oculus dexter (OD) and 20/25 oculus sinister; intraocular pressure was 52 mmHg OD. Slit-lamp examination revealed multiple round iris nodules and a 1+ inflammatory response in the anterior chamber of the right eye. Despite the maximimal tolerated medical therapy and laser trabeculotomy, the intraocular pressure was not controlled. Because iris metastasis of non-small-cell lung cancer was suspected, aqueous humor cytology and iris tissue biopsy were performed. Cytological analysis did not reveal malignant cells, but histopathological examination confirmed iris metastasis of non-small-cell lung cancer. A restaging procedure for lung cancer was performed, revealing new findings of lung and pelvic bone metastasis. Conclusions Through histopathological examination, it is possible to confirm iris metastasis of malignant tumors. Op

In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.

Background: The benefits of transradial access (TRA) over transfemoral access (TFA) for bifurcation percutaneous coronary intervention (PCI) are uncertain because of the limited availability of device selection. This study aimed to compare the procedural differences and the in-hospital and long-term outcomes of TRA and TFA for bifurcation PCI using secondgeneration drug-eluting stents (DESs). Methods: Based on data from the Coronary Bifurcation Stenting Registry III, a retrospective registry of 2,648 patients undergoing bifurcation PCI with second-generation DES from 21 centers in South Korea, patients were categorized into the TRA group (n = 1,507) or the TFA group (n = 1,141). After propensity score matching (PSM), procedural differences, in-hospital outcomes, and device-oriented composite outcomes (DOCOs; a composite of cardiac death, target vessel-related myocardial infarction, and target lesion revascularization) were compared between the two groups (772 matched patients each group). Results: Despite well-balanced baseline clinical and lesion characteristics after PSM, the use of the two-stent strategy (14.2% vs. 23.7%, P = 0.001) and the incidence of in-hospital adverse outcomes, primarily driven by access site complications (2.2% vs. 4.4%, P = 0.015), were significantly lower in the TRA group than in the TFA group. At the 5-year follow-up, the incidence of DOCOs was similar between the groups (6.3% vs. 7.1%, P = 0.639). Conclusion The findings suggested that TRA may be safer than TFA for bifurcation PCI using second-generation DESs. Despite differences in treatment strategy, TRA was associated with similar long-term clinical outcomes as those of TFA. Therefore, TRA might be the preferred access for bifurcation PCI using second-generation DES.